Abeona Therapeutics Inc (ABEO)

Overview News Price History Option Chain Discussions Forecast Stock Split

Abeona Therapeutics Inc stock is currently priced at $7.57, with a 24-hour trading volume of 386.26K. It has seen a +0.53% increased in the last 24 hours and a +0.00% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $7.74 pivot point. If it approaches the $7.30 support level, significant changes may occur.

Abeona Therapeutics Inc Stock (ABEO) Financials Data

Abeona Therapeutics Inc (ABEO) Net Income 2024

ABEO net income (TTM) was -$54.19 million for the quarter ending December 31, 2023, a -36.51% decrease year-over-year.

Abeona Therapeutics Inc (ABEO) Cash Flow 2024

ABEO recorded a free cash flow (TTM) of -$37.34 million for the quarter ending December 31, 2023, a +14.38% increase year-over-year.

Abeona Therapeutics Inc (ABEO) Earnings per Share 2024

ABEO earnings per share (TTM) was -$2.58 for the quarter ending December 31, 2023, a +60.68% growth year-over-year.

Abeona Therapeutics Inc Stock (ABEO) Latest News

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

GlobeNewswire Inc.

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

Benzinga

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

GlobeNewswire Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Upgrade	Cantor Fitzgerald: Neutral → Overweight	Nov-11-20
Initiated	B. Riley FBR: Buy	Sep-18-20
Initiated	SVB Leerink: Outperform	Feb-10-20
Resumed	Cantor Fitzgerald: Neutral	Dec-10-19
Downgrade	Maxim Group: Buy → Hold	Aug-15-19
Downgrade	Cantor Fitzgerald: Overweight → Neutral	Aug-12-19
Downgrade	Mizuho: Buy → Neutral	Jul-26-19
Initiated	Mizuho: Buy	Jun-27-19
Initiated	Mizuho: Buy	Oct-12-18
Initiated	Seaport Global Securities: Buy	Jun-05-18
Initiated	SunTrust: Buy	Nov-08-17
Reiterated	H.C. Wainwright: Buy	Oct-16-17
Reiterated	Cantor Fitzgerald: Overweight	Oct-11-17
Initiated	Citigroup: Buy	Oct-10-17
Reiterated	Maxim Group: Buy	Oct-05-17
Initiated	RBC Capital Mkts: Outperform	Sep-15-17
Reiterated	Maxim Group: Buy	Jul-18-17
Resumed	Jefferies: Buy	Jun-22-17
Initiated	Jefferies: Buy	Jan-06-17
Reiterated	Maxim Group: Buy	Sep-29-16